UBS Upgrades Straumann to Buy as Earnings Outlook Improves

Swan.my.id - Switzerland, UBS has upgraded Straumann Group to “Buy” from “Neutral”, ending a five-year period of caution toward the Swiss dental company’s shares. The bank cited improving revenue momentum and a more attractive valuation as key reasons for the upgrade.

UBS also raised its 12-month price target for Straumann to CHF 115 from CHF 90. Based on the previous closing price of CHF 93.20, the new target implies potential upside of about 23%.

The upgrade marks a notable change in UBS’s view after several years of caution. Analysts previously remained concerned that market expectations for Straumann had become too ambitious. However, UBS now believes consensus estimates have reset to more achievable levels.

UBS Turns More Positive on Straumann

UBS expects Straumann to deliver organic revenue growth of 10.3% and a core EBIT margin of 26.1% in the second half of 2026. Both forecasts stand above current consensus expectations of 9.8% revenue growth and a 25.7% core EBIT margin.

Moreover, UBS sees further room for margin expansion in 2027. The bank forecasts an 80-basis-point increase in the margin, compared with the 30 basis points implied by market consensus.

That forecast also exceeds Straumann’s medium-term framework, which calls for margin expansion of between 40 and 50 basis points. UBS expects cost savings from the company’s manufacturing facility in Shanghai and operating leverage to support the improvement.

“We no longer think consensus estimates are persistently too ambitious, and view consensus as at least achievable, with potential for an upside,” UBS analyst Graham Doyle wrote in a note to clients.

As a result, UBS now sees a more balanced relationship between expectations and Straumann’s potential financial performance.

China and US Risks Become More Manageable

The rating upgrade also reflects a reduction in several concerns that had weighed on investors. These include China’s Volume-Based Procurement, or VBP, policy, demand in the United States, and working capital requirements.

In particular, UBS expects the next round of China’s VBP process to result in a moderate price decline of between 10% and 15%. However, the bank expects Straumann to offset much of that impact through higher volumes and market-share gains.

Therefore, the potential pricing pressure does not appear as severe in UBS’s latest assessment.

The broader dental industry is also expected to remain stable. Nevertheless, UBS believes Straumann can continue to outperform the wider market by gaining market share.

The company’s iEXCEL product line represents one of the factors supporting that expectation. UBS expects the product range to contribute to further market-share gains as Straumann continues to compete across the dental market.

Straumann Sees Support From Cash Flow

Working capital had also raised concerns during the first half of the year, particularly because of growth in receivables. UBS, however, believes seasonal factors exaggerated that increase.

The bank expects receivables to normalize. Consequently, the normalization could support Straumann’s free cash flow conversion.

Free cash flow remains an important consideration for investors because it provides a clearer view of the cash the company can generate after accounting for its operating needs and investments.

Meanwhile, UBS believes the company’s improving earnings momentum could help strengthen the investment case for the shares.

The combination of revenue growth, potential margin expansion, cost savings and improving cash flow therefore forms a central part of the bank’s more positive assessment.

Straumann Valuation Looks More Attractive

Valuation has also become an important factor behind UBS’s decision to upgrade the stock.

Straumann currently trades at a price-to-earnings premium of 10% compared with the European Healthcare index. That premium sits well below the company’s 10-year average premium of 40%.

In other words, the current valuation does not reflect the same level of premium seen historically.

UBS therefore sees room for a significant valuation re-rating if Straumann’s earnings momentum continues to improve. A re-rating could occur if investors become more confident in the company’s growth and profitability outlook.

However, valuation alone does not remove the risks facing the business. China’s VBP policy, US demand and working capital remain important factors for investors to monitor.

UBS Raises Its Price Target to CHF 115

The new UBS price target stands at CHF 115, compared with the previous target of CHF 90. The increase represents a CHF 25 rise in the bank’s target valuation.

Based on the previous closing price of CHF 93.20, UBS sees around 23% potential upside.

The shares were also shown trading at CHF 96.60, up CHF 2.70, or 2.88%, according to the market data accompanying the report.

The figures highlight the positive market reaction around the stock while also showing why valuation remains central to the UBS thesis.

For investors watching Straumann, several developments now stand out:

• UBS upgraded the stock to “Buy” from “Neutral”.
• The 12-month price target increased to CHF 115 from CHF 90.
• UBS expects 10.3% organic revenue growth in the second half of 2026.
• UBS forecasts a 26.1% core EBIT margin for the same period.
• The bank expects an 80-basis-point margin expansion in 2027.
• China’s next VBP round could bring a 10% to 15% price decline.
• UBS expects higher volumes and market-share gains to offset much of the pricing impact.
• Straumann trades at a 10% P/E premium to the European Healthcare index, below its 10-year average premium of 40%.

What the UBS Upgrade Means for Straumann

The UBS upgrade represents a significant shift in its assessment of Straumann after five years of caution. The bank now sees consensus expectations as more realistic and believes the company has several potential drivers for improved earnings.

Revenue momentum could provide the first major support. At the same time, margin expansion could strengthen profitability if cost savings and operating leverage develop as UBS expects.

Furthermore, market-share gains through the iEXCEL product line could help Straumann outperform a stable industry environment.

Still, investors should consider the remaining risks. China’s VBP policy could pressure prices, while US demand and working capital trends could influence future results.

Overall, UBS’s new “Buy” rating reflects a more constructive view of Straumann’s earnings outlook and valuation. The higher CHF 115 price target also signals that the bank now sees greater potential in the shares than it did previously.

Conclusion

UBS has shifted its stance on Straumann from “Neutral” to “Buy” after five years of caution. The bank points to improving revenue momentum, achievable market expectations, potential margin expansion and a more attractive valuation.

Moreover, UBS believes risks from China’s VBP policy can remain manageable as volume growth and market-share gains offset much of the expected pricing pressure.

For now, the key factors to watch are Straumann’s revenue growth, margin performance, cash flow conversion and ability to expand its market share. These factors will determine whether the more optimistic outlook behind the UBS upgrade can continue to gain support.

FAQ

Why did UBS upgrade Straumann to Buy?

UBS upgraded Straumann because it sees improving earnings momentum, more achievable consensus expectations and a more attractive valuation.

What is UBS’s new Straumann price target?

UBS raised its 12-month price target to CHF 115 from CHF 90.

How much upside does UBS see?

Based on Straumann’s previous closing price of CHF 93.20, UBS’s new target implies potential upside of about 23%.

What risks does Straumann face?

Key risks include China’s Volume-Based Procurement policy, US demand and working capital requirements.

What is UBS forecasting for Straumann in the second half of 2026?

UBS forecasts 10.3% organic revenue growth and a 26.1% core EBIT margin for the second half of 2026.